This document discusses transient tachypnea of the newborn (TTN). TTN is a common condition caused by a delay in clearing fetal lung fluid after birth. It presents with respiratory distress and affects up to 15% of preterm infants. Risk factors include cesarean delivery, prematurity, and gestational diabetes. Diagnosis is based on clinical presentation, physical exam, and chest x-ray findings showing diffuse haziness. Treatment involves respiratory support and monitoring as symptoms typically resolve within 3 days. Medications are not routinely used or recommended for TTN management.
Introduction of Dr. Tarek s Kotb, overview of common conditions related to transient tachypnea of the newborn (TTN). Key topics include TTN diagnosis challenges.
Objectives include understanding TTN pathophysiology. Discusses fetal lung fluid importance and fluid clearance mechanisms, vital for proper respiratory function.
Discusses the incidence of TTN among infants based on gestational age and identifies key neonatal risk factors contributing to TTN development.
Signs of respiratory distress in TTN include tachypnea, nasal flaring, and retractions. Diagnosis is made through clinical presentation and radiographic findings.
Describes radiological and ultrasound findings consistent with TTN. Highlights key indicators observed during imaging studies for accurate diagnosis.
General management strategies for TTN emphasize respiratory support, nutrition, and the usage of specific medications. Discusses the ineffective diuretics and potential benefits of inhaled agents.
Addresses future research on TTN's association with asthma and stresses the need for bedside ultrasound in NICUs for enhanced diagnosis and treatment.
DR TAREK SKOTB
MBBCH
MRCPCH.UK
NRP INSTRUCTOR
PALS INSTRUCTOR
2.
WHY TTN
RDS AIRLEAK
PPHN
Malformations
CDH
SEPSIS
METABOLIS
M
MAS
PNEUMONIACHD
3.
TTN IS AVERY COMMON
DISEASE, BUT OFTEN
PRESENTS A DIAGNOSTIC
AND THERAPEUTIC
DILEMMA FOR THE
CLINICIAN….
•Miller MJ, Fanaroff AA, Martin RJ: Respiratory disorders in preterm
and term infants. In: Fanaroff AA, Martin RJ, eds. Neonatal-
perinatal medicine: Diseases of the Fetus and Infant. 6th ed. St
Louis: Mosby-Year Book; 1997: 1040-65.
4.
OBJECTIVES
1.Understand the pathophysiologyof transient
tachypnea of the newborn (TTN(.
2.Identify risk factors , clinical symptoms , and
radiographic findings in infants with TTN.
3.Appreciate the differential diagnoses for TTN.
4.Describe the typical clinical course of an infant
with TTN.
5.
INTRODUCTION
Fetal lungs arefilled with liquid that is crucial for normal lung
growth.
Vascular
channels
Pulmonary
epithelial
channels
Lymphatic
channels
6.
A DELAY INflUID CLEARANCE LEADS TO
INEFFECTIVE GAS EXCHANGE AND RESULTS IN
RESPIRATORY DISTRESS. THIS IMPERMANENT
CONDITION OF RETAINED FETAL LUNG flUID IS
KNOWN AS TRANSIENT TACHYPNEA OF THE
NEWBORN (TTN(.
7.
CHOOSE THE CORRECTANSWER
THE BULK OF FLUID CLEARANCE IS
MEDIATED BY:-
1- UTERINE CONTRACTIONS
2- PASSAGE OF BABY THROUGH BIRTH
CANAL
3- CORTISOL AND CATECHOLAMINE
SURGE(MATERNAL HORMONES(
8.
The bulk ofthis fluid clearance is mediated by
transepithelial sodium reabsorption through
amiloride-sensitive sodium channels in the alveolar
epithelial cells with only a limited contribution from
mechanical factors and Starling forces.
Semin Perinatol.2006Feb;30(1):34-43.
9.
Which of thefollowing statements
concerning the occurrence of transient
tachypnea of the newborn (TTN) is correct?
a. Female infants are at higher risk of TTN than male infants
b. Maternal gestational diabetes does not increase the risk of TTN.
c. Both small-and large-for-gestational age infants are at increased risk of
developing TTN
.
d. TTN occurs in 10% to 15% of infants born at term.
10.
INCIDENCE
TTN is oneof the most common causes of neonatal
respiratory distress.
TTN occurs in 10% of infants born between 33 and 34
weeks of gestation,
5%of infants delivered at 35to 36weeks,
And fewer than1% of all term infants
11.
NEONATAL RISK FACTORSFOR THE
DEVELOPMENT OF TRANSIENT
TACHYPNEA OF THE NEWBORN (TTN(
•Delivery before completing 39 weeks of gestation
•Cesarean section without labor
•Prematurity
•Male sex
•Large for gestational age
•Small for gestational age
•Perinatal asphyxia
•Maternal asthma
•Maternal gestational diabetes
12.
CLINICAL PRESENTATION
They havesigns of respiratory distress such as
tachypnea (respiratory rate >60 breaths/min(,
nasal flaring,
grunting, and intercostal, subcostal, and/or suprasternal
retractions.
On auscultation, breath sounds may be diminished, crackles
may be appreciated, or lung fields may be clear. Tachycardia
may often be associated.
13.
DIAGNOSIS
IS IT TRUETHAT TTN A DIAGNOSIS OF
EXCLUSION?
The diagnosis is made based on an infant’s
clinical
Presentation ,physical examination findings , and
chest radiography findings.
If symptoms persist beyond 72 hours after
birth ,alternative diagnosis to TTN must be
examine.
RESPIRATORY MANAGEMENT
Neonates withTTN may require noninvasive respiratory
support (eg, nasal cannula, nasal CPAP) and may need
supplemental oxygen to maintain normal oxygen saturation
levels.
If a newborn is requiring FiO2 greater than 0.40 or
endotracheal intubation, there is increased likelihood of
another cause of the child’s distress and reevaluation is
necessary.
24.
NUTRITION
•An infant’s respiratorycondition is the determining factor for receiving
enteral or IV nutrition. Often the clinical status and degree of tachypnea
make it unsafe for an infant to receive oral feeds and instead the infant
can receive nutrition via gavage feeding, IV solution, or a combination of
both.
26.
MEDICATIONS
•Medications studied includediuretic therapy , inhaled
racemic epinephrine, and inhaled b2-agonists. A recent
systematic review analyzed the usefulness of routine
diuretic therapy for TTN and concluded that neither oral
nor IV furosemide provided any benefit by improving
symptoms or reducing duration of hospitalization
•ReKassab M, Khriesat WM, Anabrees J. Diuretics for transient tachypnoea of
the newborn. Cochrane Database Syst Rev. 2015(11): CD003064.
doi:10.1002/14651858.CD003064.pub3
27.
MEDICATIONS
•The inhaled b2-agonistsalbutamol has been studied and may have
promise as a possible treatment option to improve respiratory
symptoms associated with TTN and decrease hospital length of stay.
Nevertheless, recent systematic reviews have concluded that more
evidence is needed to confirm the efficacy and safety of inhaled
epinephrine and b2-agonists in the treatment of TTN.
•Moresco L, Bruschettini M, Cohen A, Gaiero A, Calevo MG.
Salbutamol for transient tachypnea of the newborn. Cochrane
Database Syst Rev. 2016;(5):CD011878
28.
WHICH OF THEFOLLOWING STATEMENTS IS CORRECT
REGARDING MEDICATIONS FOR THE TREATMENT OF TTN?
A. A COCHRANE SYSTEMATIC REVIEW HAS DETERMINED
THAT INTRAVENOUS FUROSEMIDE CAN REDUCE THE
DURATION OF TACHYPNEA IN TTN BY 50% COMPARED WITH
PLACEBO.
B. TTN IS AN APPROVED INDICATION FOR INHALED NITRIC
OXIDE IN THE SETTING OF NICU ADMISSION AND NEED FOR
RESPIRATORY SUPPORT.
C. CAFFEINE HAS BEEN SHOWN IN SEVERAL RANDOMIZED
CLINICAL TRIALS TO REDUCE LENGTH OF STAY
D.MEDICATIONS SUCH AS DIURETICS AND INHALATION
AGENTS ARE NOT CURRENTLY RECOMMENDED AS
STANDARD THERAPY IN THE MANAGEMENT OF TTN
30.
FUTURE
Studies have demonstratedan association
between TTN and subsequent development
of asthma, suggesting an underlying genetic
predisposition.
Bager P, Wohlfahrt J, Westergaard T. Caesarean delivery and risk of
atopy and allergic disease: meta-analyses. Clin Exp Allergy. 2008;
38(4):634–642
31.
MESSAGE
It can bechallenging to diagnose and provide optimal
treatment for transient tachypnea of the newborn.
IT IS THE TIME FOR NEONATOLOGISTS TO USE BEDSIDE US
IN NICUS
Editor's Notes
#9 When infants are delivered near-term, especially by cesarean section (repeat or primary) before the onset of spontaneous labor, the fetus is often deprived of these hormonal changes, making the neonatal transition more difficult.